# VNX-102

Source: https://onco.cc/drugs/vnx-102/  
OnCo record `vnx-102` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VNX-102 is an experimental in vivo gene therapy from Vironexis Biotherapeutics, in preclinical development for multiple myeloma.

## Summary

VNX-102 is an in vivo gene therapy (TransJoin vectorised T-cell engager) from Vironexis Biotherapeutics. A TransJoin vectorised T-cell engager programme against BCMA and GPRC5D for multiple myeloma. Its furthest stage is preclinical development, for multiple myeloma. No clinical trial naming it is registered on ClinicalTrials.gov. Company milestone: '2026-Q1 IND enabling studies available'. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: VNX-102
- Modality: In vivo gene therapy (TransJoin vectorised T-cell engager)
- Mechanism: A TransJoin vectorised T-cell engager programme against BCMA and GPRC5D for multiple myeloma.

## Sources

- Vironexis Biotherapeutics: vironexis.com: https://vironexis.com

## Connected records

- targets: [BCMA](https://onco.cc/targets/bcma/), [GPRC5D](https://onco.cc/targets/gprc5d/)
- companies: [Vironexis Biotherapeutics](https://onco.cc/companies/vironexis-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/vnx-102.json